Aim:　We　aimed　to　investigate　the　associations　between　components　of　the　phosphatase　and　tensin　homolog　deleted　on　chromosome　10/protein　kinase　B/mammalian　target　of　rapamycin　(PTEN/AKT/mTOR)　pathway　and　liver　cancer　stem　cell　(LCSC)　markers,　including　CD133,　CD90,　CD44,　and　epithelial　cell　adhesion　molecule　(EpCAM),　and　to　further　evaluate　the　predictive　values　of　these　biomarkers　for　recurrence　and　survival　in　hepatocellular　carcinoma　(HCC).　Method:　Protein　expressions　and　mRNA　levels　of　PTEN　and　LCSC　markers　were　determined　in　110　HCC　tissues　and　98　adjacent　non-tumor　tissues.　Protein　expressions　of　phosphorylated　AKT　(p-AKT)　and　phosphorylated　mTOR　(p-mTOR)　were　detected　to　evaluate　the　activation　of　the　PTEN/AKT/mTOR　pathway　by　using　immunohistochemistry.　Prognostic　significance　was　analyzed　by　univariate　and　multivariate　analysis.　Results:　Loss　of　PTEN　expression　was　negatively　correlated　with　positive　expression　of　CD133,　CD90,　and　EpCAM　(P＜　0.05).　Positive　expression　of　p-AKT　and　p-mTOR　were　positively　associated　with　positive　expression　for　CD133,　CD90,　and　EpCAM　(P＜　0.05).　By　univariate　and　multivariate　analysis,　a　higher　level　of　a-fetoprotein,　loss　of　PTEN　expression,　and　CD133-positive,　p-AKT-positive,　p-mTOR-positive,　and　EpCAM-positive　signals　were　predictors　for　HCC　recurrence,　whereas　advanced　TNM　stage,　loss　of　PTEN　expression,　and　positive　expression　of　p-AKT,　p-mTOR,　and　CD133　were　predictors　for　survival.　Patients　with　PTEN-/CD133(+)　or　PTEN-/EpCAM(+)　HCC　had　shorter　recurrence-free　survival　and　overall　survival　times.　Conclusion:　The　PTEN/AKT/mTOR　pathway　might　play　a　crucial　role　in　driving　recurrence　and　influencing　prognosis　in　HCC.　There　could　be　a　potential　repressive　relationship　between　components　of　the　PTEN/AKT/mTOR　pathway　and　LCSCs.　The　combination　of　PTEN　with　CD133　or　EpCAM　expression　may　serve　as　a　screening　tool　to　monitor　recurrence　and　predict　prognosis.